ArticleOmics : a journal of integrative biology2014
Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis?
Article in Omics : a journal of integrative biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Comparative study of bioinformatic tools for the identification of chimeric RNAs from RNA Sequencing.RNA biology · 2021Article
- Identification of the cross-strand chimeric RNAs generated by fusions of bi-directional transcripts.Nature communications · 2021Article
- Article
- Fusion transcript detection using spatial transcriptomics.BMC medical genomics · 2020Article
- Overview of research on fusion genes in prostate cancer.Translational cancer research · 2020Review
- The landscape of chimeric RNAs in non-diseased tissues and cells.Nucleic acids research · 2020Article
- Functional heritage: the evolution of chimeric RNA into a gene.RNA biology · 2020Article
- Male-Specific Long Noncoding RNAInternational journal of molecular sciences · 2019Article
- Article
- Recurrent cis-SAGe chimeric RNA, D2HGDH-GAL3ST2, in prostate cancer.Cancer letters · 2016Article
- Intergenically Spliced Chimeric RNAs in Cancer.Trends in cancer · 2016Review
- RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.Haematologica · 2016Article
- Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications.Breast cancer research and treatment · 2016Review
- Recurrent chimeric fusion RNAs in non-cancer tissues and cells.Nucleic acids research · 2016Article
- Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation.Cell reports · 2016Article
- On the evaluation of the fidelity of supervised classifiers in the prediction of chimeric RNAs.BioData mining · 2016Article
- Role of CTCF in Regulating SLC45A3-ELK4 Chimeric RNA.PloS one · 2016Article
- High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer.International journal of clinical and experimental medicine · 2015Article
- Interstitial Deletions Generating Fusion Genes.Cancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
Chromosomal rearrangements and fusion genes play important roles in tumor development and progression. Four high-frequency prostate cancer-specific fusion genes were recently reported in Chinese cases. We attempted to confirm one of the fusion genes, USP9Y-TTTY15, by reverse transcription PCR, but detected the presence of the USP9Y-TTTY15 fusion transcript in cancer samples, nonmalignant prostate tissues, and normal tissues from other organs, demonstrating that it is a transcription-induced chimeric RNA, which is commonly produced in normal tissues. In 105 prostate cancer samples and case-matched adjacent nonmalignant tissues, we determined the expression level of USP9Y-TTTY15 and a previously reported transcription-induced chimeric RNA, SLC45A3-ELK4. The expression levels of both chimeric RNAs vary greatly in cancer and normal cells. USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer. Although the expression level of SLC45A3-ELK4 is higher in cancer than normal cells, and a dramatic increase in its expression from normal to cancer cells is correlated with advanced disease, its expression level in cancer samples alone is not correlated with any clinical parameters. These data show that both chimeric RNAs contribute less to prostate carcinogenesis than previously reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.